CMX
Chemx Materials Limited
ASX
Variation of Mercer Convertible Securities Agreement
Sentiment:
Financing Agreement Update
11 December 2024 5:11 PM
ChemX Materials (ASX:CMX) has modified its convertible securities agreement with Mercer Street Global Opportunity Fund, adjusting conversion prices and extending maturity dates for convertible notes.
Capital raise
Mercer has approved ChemX to raise up to $500,000 in additional debt financing.
Summary
- ChemX Materials has varied its agreement with Mercer Street Global Opportunity Fund regarding convertible securities.
- The conversion price for shares has been reduced from $0.06 to $0.02.
- The maturity dates for both tranche 1 and tranche 2 convertible notes have been extended to March 30, 2026.
- ChemX will make payments of $25,000 by December 31, 2024, and $400,000 by February 28, 2025, towards repayment of tranche 1 convertible notes.
- Mercer has approved ChemX to raise up to $500,000 in additional debt.
- Shareholder and ASX approval is required for these changes by February 28, 2025.
Sentiment
Score: 7
Explanation: The agreement variations appear generally positive for ChemX, providing financial flexibility and extending timelines. However, the need for approvals and upcoming payment obligations introduce some uncertainty.
Highlights
- The conversion price of shares has been lowered from $0.06 to $0.02.
- Maturity dates for $175,000 worth of tranche 1 convertible notes and $2,040,000 worth of tranche 2 convertible notes have been extended to March 30, 2026.
- ChemX will repay $25,000 of tranche 1 notes by December 31, 2024, and a further $400,000 by February 28, 2025.
- ChemX has the option to raise up to $500,000 in additional debt.
Positives
- The lower conversion price of $0.02 is beneficial for ChemX, potentially reducing dilution for existing shareholders.
- Extending the maturity dates provides ChemX with more time to complete its pilot plant and secure further funding.
- The approved additional debt of up to $500,000 offers ChemX increased financial flexibility.
Negatives
- The need for shareholder and ASX approval introduces uncertainty to the agreement variations.
- The required payments of $25,000 and $400,000 by specified dates place short-term financial demands on ChemX.
Risks
- Failure to obtain shareholder or ASX approval could jeopardize the amended agreement and impact ChemX's financial stability.
- The ability of ChemX to successfully raise additional debt is uncertain and depends on market conditions and investor interest.
- The extended timeframe for the convertible notes increases the risk of potential future changes in interest rates or market conditions that could negatively impact ChemX.
Future Outlook
ChemX aims to complete its pilot plant and pursue further funding, with the amended agreement providing greater flexibility in achieving these goals.
Management Comments
- The Company is pleased with the amended terms of the Convertible Securities Agreement which will allow for flexibility in the period ahead for the Company to complete the Pilot Plant and work towards further funding.
Industry Context
The agreement variation reflects the challenges faced by companies in the critical materials sector in securing funding for development projects. The lower conversion price and extended maturity dates could indicate a need for ChemX to attract further investment and demonstrate progress with its pilot plant.
Next Steps
- ChemX needs to secure shareholder and ASX approval for the agreement variations by February 28, 2025.
- ChemX will make payments of $25,000 and $400,000 towards the convertible notes by December 31, 2024, and February 28, 2025, respectively.
- ChemX may raise up to $500,000 in additional debt financing.
Key Dates
- 31 December 2024: $25,000 payment due for tranche 1 convertible notes
- 28 February 2025: $400,000 payment due for tranche 1 convertible notes and deadline for shareholder and ASX approval
- 30 March 2026: Extended maturity date for tranche 1 and tranche 2 convertible notes
Keywords
ChemX Materials, CMX, ASX, High Purity Alumina, HPA, Convertible Securities, Mercer Street Global Opportunity Fund, Debt Financing, Pilot Plant
CMX
Chemx Materials Limited
ASX
Sector: Materials
Filings with Classifications
Capital raise
13 April 2025 9:55 PM
Insolvency Announcement
- Benelong Capital Partners (BCP) recapitalisation proposal requires ASIC, ASX and shareholder approval.
Worse than expected
29 December 2024 5:48 PM
Trading Suspension Extension Request
- The company is not ready to announce a Funding Update and Management Restructure, which is causing a delay in trading and is worse than expected.
Delay expected
29 December 2024 5:48 PM
Trading Suspension Extension Request
- The company is delaying the release of the Funding Update and Management Restructure announcement.
- The trading suspension is being extended due to the delay in the announcement.
Delay expected
22 December 2024 5:25 PM
Trading Suspension Update
- The company's funding update and management restructure are taking longer than anticipated.
- Negotiations with relevant parties have caused a delay in the announcement.
Capital raise
18 December 2024 5:08 PM
Suspension Announcement
- The announcement is related to an update on funding, which could indicate a potential capital raise.
Capital raise
16 December 2024 5:06 PM
Trading Halt Request
- The trading halt is pending an announcement regarding an update on funding, which could indicate a potential capital raise.
Capital raise
11 December 2024 5:11 PM
Financing Agreement Update
- Mercer has approved ChemX to raise up to $500,000 in additional debt financing.
Delay expected
27 November 2024 9:50 PM
AGM Presentation
- The commissioning of the 24tpa HPA Pilot Plant has experienced unforeseen delays in recent months, primarily due to the solvent extraction (SX) module awaiting electrical package installation.
Worse than expected
27 November 2024 9:50 PM
AGM Presentation
- The announcement revealed unforeseen delays in the commissioning of the solvent extraction module of the pilot plant, pushing back the timeline for full operation.
Better than expected
13 November 2024 5:17 PM
R&D Funding Announcement
- The receipt of the R&D refund exceeding the amount of the Radium Capital facility was better than expected, resulting in a surplus for working capital.
Capital raise
7 November 2024 1:19 AM
Price Query Response
- ChemX is in discussions with third parties regarding potential capital raisings.
- No formal agreements have been reached for any capital raising.
Capital raise
30 October 2024 9:06 PM
Quarterly Report
- The company has appointed TritonLake as Corporate and Financial Advisors to assist with capital, financing and corporate advisory.
- The company believes it would be successful with raising additional capital.
Worse than expected
30 October 2024 9:06 PM
Quarterly Report
- The delays in the Solvent Extraction module of the pilot plant represent a setback from the expected timeline for commissioning.
Delay expected
30 October 2024 9:06 PM
Quarterly Report
- Delays were experienced in the construction of the Solvent Extraction (SX) module due to longer than expected lead times on key process equipment and delivery of critical electrical infrastructure.
Capital raise
24 October 2024 6:10 PM
Notice of Annual General Meeting
- The 7.1A mandate seeks shareholder approval to issue up to 10% of the company's issued capital in equity securities without further shareholder approval.
- The funds raised under the 7.1A mandate are intended to be used for the 24tpa HiPurA high purity alumina (HPA) pilot plant and working capital.
Worse than expected
23 October 2024 5:19 AM
Annual Report
- The company reported a net loss after tax of \$4.49 million, significantly higher than the previous year's loss of \$4.18 million, indicating worse than expected results.
Capital raise
23 October 2024 5:19 AM
Annual Report
- The company raised \$1,616,600 through a share placement and share purchase plan.
- A \$6,000,000 convertible note funding facility was secured, with potential for further equity dilution upon conversion.
Capital raise
30 July 2024 4:54 AM
Quarterly Activities Report
- The company has applied for an advance from a funding provider against expected CMX FY24 R&D claim for circa $440,000.
- The Company also has access to financial markets and believes it can successfully raise capital.
Capital raise
29 April 2024 7:02 PM
Quarterly Activities Report
- The company completed a $1.1M placement.
- A Share Purchase Plan (SPP) is ongoing, aiming to raise up to $500,000.
- Directors have committed to subscribe for 1,354,166 shares, subject to shareholder approval, under the Placement to raise an additional $65,000 at the same issue price.
Delay expected
21 April 2024 7:10 PM
Share Purchase Plan Extension Announcement
- The closing date of the SPP has been extended from April 23, 2024, to May 10, 2024.
Capital raise
2 April 2024 5:48 PM
Share Purchase Plan Announcement
- The document mentions that it is highly likely that further funding will be required to meet the medium to long term working capital costs of the Company.
- Any additional equity financing will dilute shareholdings, and debt financing, if available, may involve restrictions on financing and operating activities.
Capital raise
13 March 2024 2:33 AM
Interim Report
- The company has access to a further $3,800,000 funding under its unsecured convertible note facility, subject to further agreement between the parties.
Worse than expected
13 March 2024 2:33 AM
Interim Report
- The company reported a net loss of $1,911,696 for the half-year ended December 31, 2023, which is worse than breakeven.
Disclaimer: This summary was generated by artificial intelligence and its accuracy is not guaranteed. The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.